BiochemProbe — Life Science Research Reagents

SAGE-718 free base · Synonyms: Dalzanemdor

Dalzanemdor is an NMDA receptor-positive modulator of metabolism.

For research use only. Not for human or veterinary use.

Target NMDAR,iGluR
Purity >98% Stock Inquire

SAGE-718 structure

CAS No.: 1629853-48-0

Download structure (.mol)

Pack sizes & pricing

Size Price SKU Stock
1 mg USD 420.00 BP-01913-1mg In stock Get quote
5 mg USD 780.00 BP-01913-5mg In stock Get quote
10 mg USD 1,080.00 BP-01913-10mg In stock Get quote
25 mg USD 1,480.00 BP-01913-25mg In stock Get quote
50 mg USD 2,080.00 BP-01913-50mg In stock Get quote
100 mg USD 2,980.00 BP-01913-100mg In stock Get quote
250 mg Inquire BP-01913-250mg In stock Inquire
500 mg Inquire BP-01913-500mg Inquire Inquire

Need another size or custom synthesis? Request a quote.

Description

Dalzanemdor (SAGE-718) is an NMDA receptor-positive modulator of metabolism that can be used to study Huntington's chorea, Alzheimer's disease, and cognitive dysfunction.

Biological activity

In vivo SAGE-718 (Dalzanemdor) (5), a potent and high intrinsic activity NMDAR PAM with an optimized pharmacokinetic profile for oral dosing. Compound 5 has completed phase 1 single ascending dose and multiple ascending dose clinical trials and is currently undergoing phase 2 clinical trials for the treatment of cognitive impairment in Huntington's disease.

Identifiers

SMILES
C[C@@]12[C@@]3([C@]([C@]4([C@](C)(CC3)[C@@]([C@@H](CC[C@](C(F)(F)F)(C)O)C)(CC4)[H])[H])(CC=C1C[C@@](C)(O)CC2)[H])[H]
InChIKey
BVBRUQYHUXKZMQ-JNVAYQLDSA-N

Specifications

MW (average)
456.6243
Formula
C27H43F3O2
CAS No.
1629853-48-0
Physical state
Solid
Color
White to off-white
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage
Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

References

[1]. Beckley, Jacob T et al. “Pharmacological characterization of SAGE-718, a novel positive allosteric modulator of N-methyl-d-aspartate receptors.” British journal of pharmacology vol. 181,7 (2024): 1028-1050. doi:10.1111/bph.16235
[2]. Hill, Matthew D et al. “SAGE-718: A First-in-Class N-Methyl-d-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment.” Journal of medicinal chemistry vol. 65,13 (2022): 9063-9075. doi:10.1021/acs.jmedchem.2c00313

Recently viewed